Nonalcoholic steatohepatitis (NASH) progresses from simple nonalcoholic fatty liver (NAFL) and has a poor prognosis. Abnormal lipid metabolism is closely related to the occurrence and development of nonalcoholic fatty liver disease (NAFLD). This study aimed to study the relationships between serum lipid metabolites and NASH, and to improve the early diagnosis of NASH. This study included 86 NAFLD patients (23 NASH and 63 NAFL), and 81 unaffected individuals as controls from West China Hospital between October 2018 and May 2019. With lipid metabolites as the focus of the study, the differences in lipid metabolites were compared between the control group, NAFL patients, and NASH patients. Logistic regression analysis was used to examine the risk factors of NASH. Finally, receiver operating characteristic curve (ROC curve) was used to analyze the efficacy of the metabolites in NASH prediction. The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lipoprotein A (LPA) increased with the severity of NAFLD. In NAFLD patients, LPA (OR:1.61; 95%CI: 1.03–2.52) was a potential risk factor for NASH, and ROC analysis showed that the combination of LPA, ALT, and AST had a greater predictive efficiency for NASH. Abnormal apolipoprotein/lipoprotein is closely related to lipid metabolism disorder in patients with NAFLD. In NAFL, the combination of LPA, ALT, and AST contributes to predicting the occurrence of NASH. LPA may be a potential biomarker and therapeutic target for diagnosing and treating NASH.

中文翻译：

---

脂蛋白A与丙氨酸氨基转移酶和天冬氨酸氨基转移酶结合，有助于预测NASH的发生：一项横断面研究。

非酒精性脂肪性肝炎（NASH）由单纯非酒精性脂肪肝（NAFL）演变而来，预后较差。脂质代谢异常与非酒精性脂肪肝疾病（NAFLD）的发生和发展密切相关。这项研究旨在研究血清脂质代谢产物与NASH的关系，并改善NASH的早期诊断。该研究包括2018年10月至2019年5月间来自华西医院的86例NAFLD患者（23例NASH和63例NAFL），以及81例未受影响的患者作为对照。以脂质代谢物为研究重点，比较了两种药物之间的脂质代谢物差异对照组，NAFL患者和NASH患者。用Logistic回归分析检查NASH的危险因素。最后，接受者操作特征曲线（ROC曲线）用于分析代谢物在NASH预测中的功效。丙氨酸氨基转移酶（ALT），天冬氨酸氨基转移酶（AST）和脂蛋白A（LPA）的水平随NAFLD的严重程度而增加。在NAFLD患者中，LPA（OR：1.61； 95％CI：1.03-2.52）是NASH的潜在危险因素，ROC分析表明，LPA，ALT和AST的组合对NASH的预测效率更高。脂蛋白/脂蛋白异常与NAFLD患者的脂质代谢异常密切相关。在NAFL中，LPA，ALT和AST的组合有助于预测NASH的发生。LPA可能是诊断和治疗NASH的潜在生物标志物和治疗靶标。天冬氨酸转氨酶（AST）和脂蛋白A（LPA）随NAFLD的严重程度而增加。在NAFLD患者中，LPA（OR：1.61； 95％CI：1.03-2.52）是NASH的潜在危险因素，ROC分析表明，LPA，ALT和AST的组合对NASH的预测效率更高。脂蛋白/脂蛋白异常与NAFLD患者的脂质代谢异常密切相关。在NAFL中，LPA，ALT和AST的组合有助于预测NASH的发生。LPA可能是诊断和治疗NASH的潜在生物标志物和治疗靶标。天冬氨酸转氨酶（AST）和脂蛋白A（LPA）随NAFLD的严重程度而增加。在NAFLD患者中，LPA（OR：1.61； 95％CI：1.03-2.52）是NASH的潜在危险因素，ROC分析表明，LPA，ALT和AST的组合对NASH的预测效率更高。异常载脂蛋白/脂蛋白与NAFLD患者的脂质代谢紊乱密切相关。在NAFL中，LPA，ALT和AST的组合有助于预测NASH的发生。LPA可能是诊断和治疗NASH的潜在生物标志物和治疗靶标。AST对NASH的预测效率更高。异常载脂蛋白/脂蛋白与NAFLD患者的脂质代谢紊乱密切相关。在NAFL中，LPA，ALT和AST的组合有助于预测NASH的发生。LPA可能是诊断和治疗NASH的潜在生物标志物和治疗靶标。AST对NASH的预测效率更高。异常载脂蛋白/脂蛋白与NAFLD患者的脂质代谢紊乱密切相关。在NAFL中，LPA，ALT和AST的组合有助于预测NASH的发生。LPA可能是诊断和治疗NASH的潜在生物标志物和治疗靶标。